Low- and high-grade bladder cancer appraisal via serum-based proteomics approach

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 97-103

  Bansal, Navneeta ^a   Gupta, Ashish ^b   Sankhwar, Satya Narain ^a   Mahdi, Abbas Ali ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Serum proteomics; Two dimensional gel electrophoresis; Urinary bladder cancer

Indexed keywords

CALGRANULIN A; CALGRANULIN B; PROTEOME; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INSTRUMENT VALIDATION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMALLY INVASIVE PROCEDURE; MOLECULAR PROBE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TUMOR DIFFERENTIATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; BLOOD; CASE-CONTROL STUDIES; HUMANS; METABOLISM; METHODS; MIDDLE AGED; NEOPLASM GRADING; PATHOLOGY; REPRODUCIBILITY OF RESULTS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84901989934     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.05.012     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2009, 59:225-249.
2. Salehi A., Khezri A.A., Malekmakan L., Minsharifi A. Epidemiologic status of bladder cancer in Shiraz, Southern Iran. Asian Pac J Cancer Prev 2011, 12:1323-1327.
3. Olaf P.J., Vrooman J., Alfred W. Urinary markers in bladder cancer. Eur Urol 2008, 53:909-916.
4. Toma M.I., Friedrich M.G., Hautmann S.H., et al. Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer. World J Urol 2004, 22:145-149.
5. Schwamborn K., Krieg R.C., Grosse J., et al. Serum proteomic profiling in patients with bladder, cancer. Eur Urol 2009, 56:989-997.
6. Minami S., Sato Y., Matsumoto T., et al. Proteomic study of sera from patients with bladder cancer: usefulness of S100A8 and S100A9 proteins. Cancer Genomics Proteomics 2010, 7:181-190.
7. Tolson J.P., Flad T., Gnau V., Dihazi H., et al. Differential detection of S100A8 in transitional cell carcinoma of bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006, 6:697-708.
8. Levett D., Flecknell P.A., Rudland P.S., Barraclough R., et al. Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. Am J Pathol 2002, 160:693-700.
9. Agerbaek M., Alsner J., Marcussen N., Lundbeck F., Maase H.V.D. Focal S100A4 protein expression is an independent predictor of development of metastatic disease in cystectomized bladder cancer patients. Eur Urol 2006, 50:777-785.
10. Wu T.F., Wu H., Vhow N.H., Liao C.F., Liu H.S. Proteomic analysis of bladder cancer cells reveals potential candidates of biomarkers in bladder tumorigenesis. Cancer Genomics Proteomics 2005, 2:151-158.
11. Memon A.A., Sorensen B.S., Meldgaard P., Fokdal L., Thykjaer T., Nexo E. Down-regulation of S100C is associated with bladder cancer progression and poor survival. Clin Cancer Res 2005, 11:606-611.
12. Celis J.E., Celis P., Palsdottir H., Ostergaard M., Gromov P., et al. Proteomic strategies to reveal tumor heterogeneity among urothelial-papillomas. Mol Cell Proteomics 2002, 1:269-279.
13. Lee Y.R., Chen Y.W., Tsai M.C., et al. Redox- and expression-proteomic analysis of plasma biomarkers in bladder transitional cell carcinoma. Mol Biosyst 2012, 8:3314-3324.
14. Yao R., Davidson D.D., Beltran A.L., et al. The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol 2007, 22:1025-1032.
15. Kriajevska M., Fischer L.M., Moertz E., et al. Liprinβ1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1). J Biol Chem 2002, 277:5229-5235.
16. Yammani R.R., Carlson C.S., Bresnick A.R., et al. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: role of the receptor for advanced glycation end products. Arthritis Rheum 2006, 54:2901-2911.
17. Moriyama K.M., Endo Y., Yonemura Y., et al. S100A4 regulates E-cadherin expression in oral squamous cell carcinoma. Cancer Lett 2005, 230:211-218.
18. Kimura K., Endo Y., Yonemura Y., et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000, 6:1125-1131.
19. Sacka U., Walther W., Scudiero D., et al. S100A4-induced cell motility and metastasis is restricted by the Wnt/β-catenin pathway inhibitor calcimycin in colon cancer cells. Mol Biol Cell 2011, 22:3344-3354.
20. Grebhardt S., Veltkamp C., Strobel P., Mayer D. Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer 2012, 131:2785-2794.
21. Turovskaya O., Foell D., Sinha P., et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008, 29:2035-2043.
22. Ghavami S., Rashedi I., Dattilo B.M., et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008, 83:1484-1492.
23. Bianchi M.E. DaMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
24. Ghavami S., Chitayat S., Hashemi M., et al. S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol 2009, 625:73-83.
25. Ebbing J., Mathia S., Seibert F.S., et al. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder. World J Urol 2013, (in press).
26. Chiche J., Ilc K., Laferrière J., et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009, 69:358-368.
27. Swietach P., Patiar S., Supuran C.T., et al. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem 2009, 284:20299-20310.
28. +2 -dependent apoptosis. Proc Natl Acad Sci U S A 2002, 99:8054-8059.
29. Kirsch T., Nah H.D., Demuth D.R., et al. Annexin V-mediated calcium flux across membranes is dependent on the lipid composition: implications for cartilage mineralization. Biochemistry 1997, 36:3359-3367.
30. Wang W., Xu J., Kirsch T. Annexin V and terminal differentiation of growth plate chondrocytes. Exp Cell Res 2005, 305:156-165.